Physician profile
Timothy Krill
NPI 1457770067
$5,754.01
in general payments reported to CMS, 2019-2025
25 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $102 · 2021: $34.84 · 2022: $403 · 2023: $1,321 · 2024: $1,699 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,506.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,816.71 | 2019-2025 | |
| Janssen Biotech, INC. | $883.92 | 2022-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $759.51 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Boston Scientific Corporation | $511.98 | 2019 | |
| Madrigal Pharmaceuticals | $353.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $321.00 | 2022-2025 | |
| Genzyme Corporation | $145.51 | 2023-2025 | |
| Gilead Sciences, INC. | $126.78 | 2022-2025 | |
| Celgene Corporation | $116.83 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $103.51 | 2024-2025 | Omvoh |
| Cook Medical LLC | $96.64 | 2023-2025 | Zilver Ptx, Icast Covered Stent System, 6mmx22mmx120cm, Zilver Vena |
| Phathom Pharmaceuticals, INC. | $95.93 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $60.71 | 2023-2024 | Dupixent |
| Celltrion USA INC. | $59.95 | 2024-2025 | Vegzelma |
| Novo Nordisk INC | $46.79 | 2025 | Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.73 | 2021-2025 | Xifaxan |
| Echosens North America, INC. | $33.56 | 2025 | Fibroscan |
| Nestle Healthcare Nutrition INC. | $30.46 | 2023 | |
| Mallinckrodt Hospital Products INC. | $29.76 | 2024 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $25.02 | 2025 | Givlaari |
| Ironwood Pharmaceuticals, INC | $24.74 | 2024 | |
| Aimmune Therapeutics, INC. | $23.24 | 2025 | Zenpep |
| Exact Sciences Corporation | $16.69 | 2023 | Cologuard Collection Kit |
| Sandoz INC. | $15.94 | 2023 | |
| Redhill Biopharma INC. | $15.26 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Krill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.